| Literature DB >> 26887985 |
Luyao Chen1, Hongzhao Li1, Liangyou Gu1, Xin Ma1, Xintao Li1, Fan Zhang1, Yu Gao1, Yang Fan1, Yu Zhang1, Yongpeng Xie2, Xu Zhang1.
Abstract
The relationship between urinary collecting system invasion (UCSI) and oncological outcomes in renal cell carcinoma (RCC) patients has attracted extensive attention recent years. However, the reports were inconsistent and remain controversial. Thus, we performed a systematic literature search of PubMed, Embase, Web of Science and The Cochrane Library databases to identify relevant studies up to June 2015 and conducted a standard meta-analysis of survival outcomes. 17 studies containing 9012 RCC patients satisfied the inclusion criteria. Pooled HRs for overall survival (OS) and recurrence-free survival (RFS) were 1.45 (95%CI, 1.26-1.66, P < 0.001) and 2.27 (95% CI, 1.54-3.34, P < 0.001), respectively. Further subgroup analysis suggested that UCSI was significant associated with poor cancer-specific survival (CSS) in stage T1-T2 RCC (HR = 2.05, 95%CI: 1.43-2.96, P < 0.001) but not in stage T3-T4 tumors (HR = 1.08, 95%CI: 0.63-1.85, P = 0.771). Current evidence revealed that UCSI has a significant negative impact on OS and RFS in RCC patients and could be used to predict CSS especially in localized RCC. Thus, RCC patients with UCSI should be paid more attention by clinician and pathologist and require close follow up for their poor prognosis.Entities:
Mesh:
Year: 2016 PMID: 26887985 PMCID: PMC4758053 DOI: 10.1038/srep21325
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart of study selection.
Characteristics of eligible studies in the meta-analysis.
| Author | Year | Country | Study design | Study period | Patient | UCSI | Age (median) | Follow up (median) | outcome | Quality scores |
|---|---|---|---|---|---|---|---|---|---|---|
| Zhang | 2015 | China | Cohort study | 2008–2011 | 253 RCC | 10 | 62.5 | 32.3 months | OS | 8 |
| Brookman-May | 2011 | Europe and USA | Cohort study | 1984–2008 | 670 RCC (pT2) | 75 | 59.4 | 51 months | CSS | 8 |
| Palapattu | 2003 | USA | Cohort study | 1989–1999 | 895 RCC | 124 | 59 | 31 months | OS | 9 |
| Klatte | 2009 | USA | Cohort study | 1985–2007 | 158 pRCC | 29 | 61.9 | 38 months | CSS | 7 |
| Margulis | 2007 | USA | Cohort study | 1990–2006 | 365 RCC (pT3a) | 34 | 58.2 | 22.5 months | CSS | 8 |
| Klatte | 2007 | USA | Cohort study | 1985–2006 | 321 RCC (pT3) | 112 | 60.9 | 28 months | CSS | 7 |
| Ornellas | 2012 | Brazil | Cohort study | 2004–2010 | 227 RCC | 38 | 60 | 28 months | RFS | 8 |
| Shi | 2014 | China | Cohort study | 2000–2010 | 173 ccRCC | 28 | 53 | 61.4 months | CSS | 9 |
| Klatte | 2007 | USA | Cohort study | 1985–2005 | 519 RCC (pT1+pT2) | 39 | 61 | 49 months | RFS | 8 |
| Cho | 2009 | Korea | Cohort study | 1984–2007 | 299 ccRCC (pT1+pT2) | 42 | 56 | 52.3 months | CSS, RFS | 9 |
| Terrone | 2004 | Italy | Cohort study | 1983–1999 | 671 RCC | 59 | 60.4 | 59 months | OS, CSS | 9 |
| Sameh | 2012 | Egypt | Cohort study | 2000–2010 | 112 RCC (pT3+pT4) | 10 | 59 | 24 months | RFS | 7 |
| Schrader | 2009 | Germany | Cohort study | 1990–2005 | 780 RCC | 67 | 64 | 5.44 years | CSS | 8 |
| Anderson | 2011 | USA | Cohort study | 1988–2008 | 303 RCC (pT3) | 67 | 61.8 | 23.3 months | OS, CSS | 8 |
| Verhoest | 2009 | France and Italy | Cohort study | 1997–2004 | 754 RCC (pT1+pT2) | 35 | 61 | 43 months | CSS | 9 |
| Waalkes | 2010 | Germany | Cohort study | 1990–2005 | 1678 RCC | 149 | 62 | 5.4 years | CSS | 7 |
| Brookman-Amissah | 2010 | Germany | Cohort study | 1992–2006 | 834 RCC | 90 | 62.2 | 79 months | CSS | 9 |
Abbreviations: UCSI: urinary collecting system invasion; RCC: renal cell carcinoma; pRCC: papillary renal cell carcinoma; ccRCC: clear cell renal cell carcinoma; OS: overall survival; CSS: cancer-specific survival; RFS: recurrence-free survival.
Figure 2Forest plot of studies evaluating the association between urinary collecting system invasion and cancer-specific survival of renal cell carcinoma.
HR = hazard ratio; CI = confidence interval.
Meta-regression and subgroup analysis of the studies reporting the association of USCI and CSS of RCC.
| Subgroup | Studies | Patients | Pooled HR | 95% CI | Heterogeneity | Meta-regression |
|---|---|---|---|---|---|---|
| Ethnicity | 0.820 | |||||
| Caucasian | 10 | 6534 | 1.25 | 1.01–1.54 | 65.6% | |
| Asian | 2 | 472 | 1.13 | 0.55–2.33 | 0% | |
| No. of patients | 0.420 | |||||
| >500 | 6 | 5387 | 1.33 | 1.02–1.73 | 72.4% | |
| <500 | 6 | 1619 | 1.11 | 0.79–1.55 | 42.5% | |
| Stage | 0.041 | |||||
| T1–2 | 3 | 1723 | 2.05 | 1.43–2.96 | 0% | |
| T3–4 | 3 | 989 | 1.08 | 0.63–1.85 | 74.5% | |
| Mixed | 6 | 4294 | 1.10 | 0.94–1.30 | 26.7% | |
| Analysis | 0.643 | |||||
| univariable analysis | 2 | 664 | 1.02 | 0.59–1.75 | 0% | |
| multivariable analysis | 10 | 6342 | 1.26 | 1.02–1.56 | 65.1% |
Abbreviations: UCSI: urinary collecting system invasion; CSS: cancer-specific survival; RCC: renal cell carcinoma; HR: hazard ratio; CI: confidence interval.
Figure 3Forest plot of studies evaluating the association between urinary collecting system invasion and overall survival of renal cell carcinoma.
HR = hazard ratio; CI = confidence interval.
Figure 4Forest plot of studies evaluating the association between urinary collecting system invasion and recurrence-free survival of renal cell carcinoma.
HR = hazard ratio; CI = confidence interval.
Figure 5Funnel plots for the evaluation of potential publication bias.
(A) cancer-specific survival; (B) overall survival; (C) recurrence-free survival.